CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Sean McCarthy to moderate panel, "Bridges Over Troubled Water and M&A "a la carte": Financing and Exiting", at Bio 2010 in Chicago, IL
News | 05. 05. 2010
